Nexalin Technology Inc. (NASDAQ: NXL) completed an 8-week clinical trial in Brazil demonstrating a 77.8% anxiety response rate using its ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE